Chargement en cours...
Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients
For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most recommended method is quantitative RT-PCR (RT-qPCR) for measuring BCR-ABL1 transcripts. Several studies reported that a DNA-based assay enhances the sensitivity of detection of the BCR-ABL1 genomic rearrangement...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5834283/ https://ncbi.nlm.nih.gov/pubmed/29541390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23971 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|